NRG-DT001 phase Ib trial of neoadjuvant navtemadlin (previously AMG232 and KRT232) concurrent with preoperative radiotherapy in wild-type p53 soft tissue sarcoma of the extremity and body wall.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Meng Xu Welliver, Pedro A. Torres-Saavedra, Brian Andrew Van Tine, David G. Kirsch, Michelle A. Rudek, Paul Wakely, Gary K. Schwartz, Raphael E. Pollock, John Michael Kane, Steve B. Jiang, Alan D. Rogers, Peter Houghton, Marta Batus, Andrea Lea Johnston, Matthew Spraker, Krisha Howell, Jonathan Harris, Dian Wang
Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, NRG Oncology, Washington University in St. Louis, Duke Medical Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbia University, Roswell Park Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, The University of Texas at San Antonio Health Science Center, Rush University Medical Center, University of Oklahoma, Fox Chase Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4286297238